Share on LinkedInShare on LinkedIn

ARTICLE · 30 SEPTEMBER 2024

Late-Stage Functionalisation: A Unique Perspective From A Research Scientist Turned Patent Attorney

Marks & Clerk
Marks & Clerk
Contributor
Marks & Clerk

Marks & Clerk

Marks & Clerk LLP was founded in 1887 by George Croydon Marks, who was joined in partnership by...

View firm profile
Explore more from Marks & Clerk

Late-stage functionalisation – defined as "a desired chemoselective transformation on a complex molecule to provide at least one analog in sufficient quantity and purity for a given purpose without the necessity for installation of a functional group...

United KingdomIntellectual Property

Late-stage functionalisation – defined as "a desired chemoselective transformation on a complex molecule to provide at least one analog in sufficient quantity and purity for a given purpose without the necessity for installation of a functional group that exclusively serves the purpose to enable said transformation" 1 – has emerged as a valuable enabling tool within the arsenal of a medicinal chemist. As newer synthetic methods become developed for the generation of small molecules, so too has the chemical space that medicinal chemists will have access to.

Of course, these methods are valuable to the R&D team – but did you know that late-stage functionalisation will also likely have an impact on the IP profession? This perspective provides some insight into how late-stage functionalisation not only helps the chemists at the bench, but also the patent attorneys working in-house and within outside counsel who are very much off the bench.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from